Blueprint Medicines Corporation General and Administrative Expenses 2011-2026 | BPMC

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Blueprint Medicines Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
359 M	295 M	237 M	195 M	158 M	96.4 M	47.9 M	28 M	19.2 M	14.5 M	7.89 M	5.07 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
359 M	5.07 M	122 M

Quarterly General and Administrative Expenses Blueprint Medicines Corporation

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
95.8 M	-	89.9 M	89.3 M	83.6 M	-	70.7 M	71.9 M	71 M	-	57.6 M	58.7 M	57.1 M	-	49.8 M	49.3 M	42 M	-	37.4 M	42.2 M	35.7 M	-	25.6 M	21.9 M	16.6 M	-	12 M	12.3 M	9.91 M	-	7.38 M	6.83 M	5.68 M	-	4.89 M	4.69 M	4.65 M	-	4.22 M	3.84 M	2.77 M	-	1.92 M	1.44 M	1.57 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
95.8 M	1.44 M	33.8 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Arcturus Therapeutics Holdings ARCT	46.1 M	$ 7.42	5.55 %	$ 203 M	Israel
FSD Pharma HUGE	9.05 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	2.31 M	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	101 M	$ 1.71	5.9 %	$ 200 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
BioNTech SE BNTX	514 M	$ 92.36	0.24 %	$ 22.3 B	Germany
AstraZeneca PLC AZN	19.9 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	16.7 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	24.5 M	-	0.74 %	$ 768 M	Israel
Compugen Ltd. CGEN	8.89 M	$ 2.68	-4.29 %	$ 250 M	Israel
Abcam plc ABCM	224 M	-	-	$ 4.9 B	Britain
Galera Therapeutics GRTX	5.69 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Enlivex Therapeutics Ltd. ENLV	186 K	$ 0.68	-5.59 %	$ 31.1 M	Israel
Esperion Therapeutics ESPR	166 M	$ 3.13	-0.16 %	$ 651 M	USA
Eton Pharmaceuticals ETON	35.8 M	$ 31.34	-3.84 %	$ 843 M	USA
Affimed N.V. AFMD	24.7 M	-	-34.95 %	$ 21.5 M	Germany
Forte Biosciences FBRX	12.4 M	$ 22.15	2.59 %	$ 287 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Checkmate Pharmaceuticals CMPI	15.7 M	-	-	$ 231 M	USA
Celyad Oncology SA CYAD	10.5 M	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Generation Bio Co. GBIO	37.8 M	-	-	$ 344 M	USA
IMV IMV	17 M	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Grifols, S.A. GRFS	1.26 B	$ 8.02	0.44 %	$ 5.45 B	Spain
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Cyclacel Pharmaceuticals CYCCP	7.72 M	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	30.7 M	-	-	$ 384 M	Britain
Heron Therapeutics HRTX	54.6 M	$ 0.86	-0.05 %	$ 143 M	USA
Gracell Biotechnologies GRCL	139 M	-	-	$ 3.37 B	China
Anika Therapeutics ANIK	49.1 M	$ 14.8	-0.54 %	$ 212 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	10.1 M	-	5.93 %	$ 314 M	Canada
InflaRx N.V. IFRX	13.5 M	$ 2.73	4.62 %	$ 184 M	Germany
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 3.55	4.26 %	$ 5.84 M	Israel
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA